Table of Contents
The global autism spectrum disorders (ASD) market was valued at $346.2 million in 2013 and $360.9 million in 2014. This market is expected to grow to $412.7 million by 2019, a compound annual growth rate (CAGR) of 2.7%.
This report provides:
An overview of the regional and global markets for Autism Spectrum Disorder (ASD) therapies and diagnostics.
Analyses of global market trends, with data from 2013, 2014, and projections of compound annual growth rates (CAGRs) through 2019.
An overview of ASDs including types, epidemiology, symptoms, and causes and pathophysiology.
Coverage of approved therapies and tolerated off-label alternative treatments for ASD.
In-depth analysis of the ASD therapies market dynamics, specifically growth drivers, inhibitors, and opportunities.
A relevant patent analysis including patents nearing expiration, and recently issued patents.
Comprehensive profiles of major players in the field.
SCOPE OF THE STUDY
The scope of this study encompasses the global and regional markets for therapeutic and diagnostic technologies of ASD. BCC Research analyzed each market and its applications, regulatory environment, technology, market projections and market share. Issues discussed include the major drug profiles, technological features and trends. The global markets for the ASD therapeutics and diagnostics include selected markets in the U.S., Canada, the U.K., France, Germany, Spain, Italy and Japan. The markets of the rest of the world are not reported due to their economic insignificance for this report.
Get Industry Insights. Simply.
Talk to Veronica
+1 718 514 2762
PharmaFocus: Tauopathies - Global Market Analysis Summary Tauopathies are a class of more than 20 neurodegenerative diseases characterized by tau protein aggregation in the brain. There are currently no ...
Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Lewy Body Dementia in 12 Major Markets Dementia with Lewy Bodies (DLB) is the second most frequent cause of age related neurodegenerative ...
Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Alzheimer’s disease in 12 Major Markets Alzheimer's disease (AD) is a progressive, irreversible neurodegenerative disorder. It is ...